Myriad Genetics (NASDAQ:MYGN – Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0 ...

Research into improving the detection of ovarian cancer is set to get a boost thanks to funding from the Cancer Society.

Ovarian cancer has historically been called a “ silent killer ,” because clinicians thought its symptoms were undetectable. Patients were often diagnosed so late that doctors thought nothing could be ...

The Amsterdam-based company recently received IVDR certification for other tests including one for phenylketonuria.

The researchers found that having ever used oral contraception reduced odds of ovarian cancer by 26% (odds ratio [OR], 0.74; 95% CI, 0.66-0.84). Further, those who stopped using oral contraception at ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Johnson & Johnson is beginning its third legal battle over its baby powder product's alleged link to ovarian cancer in more ...

MRC Holland recently announced that five SALSA MLPA assays for the detection of hereditary breast and ovarian cancer (HBOC) ...

Clinical trials of a simple and accurate blood test to detect early-stage ovarian cancer – key to boosting survival rates – ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...

Johnson & Johnson is facing a critical test over its $10B proposal to end litigation alleging that its baby powder caused ovarian cancer, ...

Johnson & Johnson seeks approval for a $10 billion proposal to resolve lawsuits alleging its baby powder caused ovarian ...